Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30893008 | 0.87 | ALDH1A1 (0.56) | MRGPRX4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1286077 | 0.87 | ALDH1A1 (0.56) | MRGPRX4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1285220 | 0.87 | ALDH1A1 (0.56) | MRGPRX4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1063179 | 0.87 | ALDH1A1 (0.67) | MRGPRX4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1285085 | 0.86 | RAB9A (0.58) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL30343614 | 0.86 | RAB9A (0.58) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL20220824 | 0.86 | RAB9A (0.58) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL17631586 | 0.84 | PRKDC (0.58) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1845583 | 0.83 | MAPT (0.54) | MRGPRX4ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4250883 | 0.83 | KMO (0.68) | MRGPRX4ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MRGPRX4 548/4885ALDH1A1 1265/4885MEN1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.